RE:DUE DILEGENCE Great thanks, that is a very positive confirmation that indeed this is finally happening. As I am sure we can all agree, even the short traders, this puppy keeps eating and is on the cusp of turning the corner and becoming the top dog out there. I agree with Sunrize and others' that management has laid out timelines that are best case scenario and the Canadian timelines in particular have misguided us in terms of our investment timelines. However, the evidence is indisputable that the cultivation facility is the most adavnced, productive automated campus, anywhere in the US and gives Sunniva a huge competitive advantage for quite some time in California. For those that have hung in there, as I have, you will be rewarded after a long hard 2018 and continally declining SP and investor account. For new investors, you have stumbled across a future top US cannabis that has stumbled along, but adapted to an ever changing, evolving market place and now is on the cusp meeting their lofty initial goals. I am writing this rather long post, not to pump and try and sucker some investors to join in, but making clear what is in store going forward.
The Canadian strategy has become a reset and for good reason. The Canadian market is in crisis mode right now, with over regulations, restricted high margin products, poor quality, lack of supply due to poor execution of suppliers, etc. I agree with Scopro, that it really has been a blessing disguise. If Sunniva had received financing and constructed the now phase 1 and 2 large scale facilities they would not be profitable for the foreseeable future providing wholesale product to companies already receiving low margins at the retail level due to edible restrictions and government rules for price capping to handcuff the blackmarket. Today, the only high margin in Canada is medicinal cannabis and the NHS clinics are aligned to provide this with their 105,000 scripts and counting. The royalties that Sunniva receives from LP's is high margin and for good reason. These royalties obviously will not apply to Sunniva products (or goes into the same pot) , so effectively this will make Sunniva future product from the new Pods, untouchable in terms of competitively priced. And as we know, doctor relationships are things very much valued in Canada, meaning very little turnover of patients who will buy whatever the doctor prescribes... glta even ths short sellers as your time is at hand shortly.